A Randomized, Placebo-controlled, Double Blind Trial of Semaglutide 1mg (Ozempic®) on Regression to Normoglycemia in WomEn With a Recent History of Gestational diabETes Mellitus: The SWEET Study
Latest Information Update: 24 Jan 2024
Price :
$35 *
At a glance
- Drugs Semaglutide (Primary)
- Indications Gestational diabetes
- Focus Therapeutic Use
- Acronyms SWEET
- 18 Jan 2024 Planned End Date changed from 1 Aug 2024 to 1 Aug 2025.
- 18 Jan 2024 Planned primary completion date changed from 1 Feb 2024 to 1 May 2025.
- 25 Jan 2022 Status changed from not yet recruiting to recruiting.